PubRank

J Michael Straughn

Author PubWeight™ 64.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011 2.27
2 A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol 2006 1.77
3 The Wnt/β-catenin pathway in ovarian cancer: a review. Gynecol Oncol 2013 1.66
4 The utilization of palliative care in gynecologic oncology patients near the end of life. Gynecol Oncol 2012 1.56
5 Lynch syndrome in women less than 50 years of age with endometrial cancer. Obstet Gynecol 2008 1.54
6 Cost-effectiveness analysis of strategies for the surgical management of grade 1 endometrial adenocarcinoma. Obstet Gynecol 2007 1.49
7 Outcomes of Stage I/II vulvar cancer patients after negative superficial inguinal lymphadenectomy. Gynecol Oncol 2005 1.45
8 Pelvic umbrella pack for refractory obstetric hemorrhage secondary to posterior uterine rupture. Obstet Gynecol 2002 1.41
9 Pegylated liposomal doxorubicin consolidation therapy after platinum/paclitaxel-based chemotherapy for suboptimally debulked, advanced-stage epithelial ovarian cancer patients. Oncologist 2006 1.40
10 Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy. Gynecol Oncol 2003 1.40
11 Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. Int J Gynecol Cancer 2010 1.20
12 A cost-effectiveness analysis of management strategies for cervical intraepithelial neoplasia grades 2 and 3. Am J Obstet Gynecol 2003 1.04
13 Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol 2009 1.04
14 Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis. Cancer 2006 1.04
15 Two cases of non-Hodgkin's lymphoma presenting as primary gynecologic malignancies. Gynecol Oncol 2005 1.03
16 A prospective evaluation of "see and treat" in women with HSIL Pap smear results: is this an appropriate strategy? J Low Genit Tract Dis 2005 1.02
17 Lipoxygenase pathway receptor expression in ovarian cancer. Reprod Sci 2008 1.01
18 The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 2008 1.01
19 A prospective evaluation of a simulator-based laparoscopic training program for gynecology residents. J Am Coll Surg 2007 1.00
20 A comparison of hand-assisted laparoscopy and conventional laparotomy for the surgical evaluation of pelvic masses. Gynecol Oncol 2005 0.98
21 The effect of obesity on survival in patients with ovarian cancer. Gynecol Oncol 2008 0.98
22 Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007 0.98
23 Management strategies for abnormal early pregnancy: a cost-effectiveness analysis. J Reprod Med 2005 0.98
24 A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol 2012 0.97
25 Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 2012 0.93
26 Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol 2011 0.93
27 Preclinical studies and clinical utilization of monoclonal antibodies in epithelial ovarian cancer. Gynecol Oncol 2009 0.92
28 The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol 2009 0.92
29 Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008 0.90
30 Diagnostic loop electrosurgical excisional procedure for discrepancy: do preoperative factors predict presence of significant cervical intraepithelial neoplasia? J Low Genit Tract Dis 2007 0.90
31 Predictors of outcomes for women with cervical carcinoma. Gynecol Oncol 2005 0.89
32 The role of comprehensive surgical staging in patients with endometrial cancer. Cancer Control 2009 0.89
33 Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series. J Reprod Med 2004 0.89
34 Anti-tumor activity of the TRA-8 anti-DR5 antibody in combination with cisplatin in an ex vivo human cervical cancer model. Gynecol Oncol 2008 0.89
35 Cervical intraepithelial neoplasia in adolescent women: incidence and treatment outcomes. Obstet Gynecol 2006 0.89
36 The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 2009 0.87
37 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol 2007 0.87
38 Robotic surgery in gynecologic oncology fellowship programs in the USA: a survey of fellows and fellowship directors. Int J Med Robot 2010 0.86
39 Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg 2006 0.86
40 Uterine leiomyosarcoma metastatic to the thyroid. Obstet Gynecol 2002 0.86
41 Overcoming TRAIL resistance in ovarian carcinoma. Gynecol Oncol 2010 0.85
42 Complete uterine necrosis following chemoradiation for advanced cervical cancer: a case report. Gynecol Oncol 2007 0.84
43 Morbidity and mortality conference in obstetrics and gynecology: a tool for addressing the 6 core competencies. J Grad Med Educ 2011 0.83
44 Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol 2011 0.82
45 The role of radical parametrectomy in the treatment of occult cervical carcinoma after extrafascial hysterectomy. Gynecol Oncol 2004 0.82
46 Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003 0.82
47 Double prophylaxis for deep venous thrombosis in patients with gynecologic oncology who are undergoing laparotomy: does preoperative anticoagulation matter? Int J Gynecol Cancer 2011 0.81
48 Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer 2009 0.81
49 Management strategies for stage IB2 cervical cancer: a cost-effectiveness analysis. Gynecol Oncol 2005 0.81
50 Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients. Gynecol Oncol 2014 0.80
51 The impact of aborted radical hysterectomy in patients with cervical carcinoma. Gynecol Oncol 2004 0.80
52 Management of complex pelvic masses using a multivariate index assay: a decision analysis. Gynecol Oncol 2012 0.79
53 Cost-effectiveness analysis of sentinel lymph node biopsy in the treatment of early-stage vulvar cancer. Int J Gynecol Cancer 2014 0.79
54 Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma. Ann Surg Oncol 2013 0.78
55 The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells. Gynecol Oncol 2011 0.78
56 Combination therapy with paclitaxel, carboplatin and megestrol acetate for the management of advanced stage or recurrent carcinoma of the endometrium: a phase II study. J Reprod Med 2014 0.78
57 Use of a fascial prosthesis for management of abdominal compartment syndrome secondary to obstetric hemorrhage. Obstet Gynecol 2006 0.77
58 Life-space assessment in urogynecology and gynecological oncology surgery patients: a measure of perioperative mobility and function. J Am Geriatr Soc 2009 0.77
59 Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. Int J Gynecol Cancer 2009 0.77
60 Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol 2006 0.77
61 A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer. Gynecol Oncol 2007 0.77
62 Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy. Gynecol Oncol 2005 0.77
63 Comparison of operative risks associated with radical hysterectomy in pregnant and nonpregnant women. J Reprod Med 2013 0.77
64 Incidence of mechanical malfunction in low-profile subcutaneous implantable venous access devices in patients receiving chemotherapy for gynecologic malignancies. Gynecol Oncol 2011 0.77
65 Perioperative morbidity and mortality in octogenarians with ovarian cancer. Int J Gynecol Cancer 2013 0.76
66 Screening behaviors and cultural barriers in women with newly diagnosed cervical cancer. J Low Genit Tract Dis 2013 0.76
67 The management of cervical intraepithelial neoplasia during pregnancy: is colposcopy necessary? J Low Genit Tract Dis 2009 0.76
68 Recurrence of endometrial adenocarcinoma in a prior Bartholin's cyst marsupialization incision. Gynecol Oncol 2006 0.76
69 Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-Trastuzumab. Am J Clin Oncol 2016 0.75
70 Outcomes of patients with gynecologic malignancies undergoing video-assisted thoracoscopic surgery (VATS) and pleurodesis for malignant pleural effusion. Gynecol Oncol 2012 0.75
71 Complications of indwelling venous access devices in patients with gynecologic malignancies. Gynecol Oncol 2003 0.75
72 Constructing a Novel Simple LEEP Training Model. J Grad Med Educ 2013 0.75
73 The Evolution of and Evidence for Opportunistic Salpingectomy. Obstet Gynecol 2017 0.75
74 Does Obesity Affect Pathologic Agreement of Initial and Final Tumor Grade of Disease in Endometrial Cancer Patients? Int J Gynecol Cancer 2017 0.75
75 Outcomes of gynecologic oncology patients undergoing gastrografin small bowel follow-through studies. J Reprod Med 2014 0.75
76 Fertility sparing therapy in a patient with placental site trophoblastic tumor: a case report. Gynecol Oncol 2006 0.75
77 Completed versus aborted radical hysterectomy for node-positive stage IB cervical cancer in the modern era of chemoradiation therapy. Gynecol Oncol 2012 0.75
78 The use of retinoids in ovarian cancer: a review of the literature. Int J Gynecol Cancer 2012 0.75
79 Unilateral cervical cancer in a patient with cervix duplex. Gynecol Oncol 2006 0.75
80 Early abdominal incision recurrence in a patient with stage I adenocarcinoma of the endometrium. Obstet Gynecol 2004 0.75
81 Conservative management of postoperative Fever in gynecologic patients undergoing major abdominal or vaginal operations. J Am Coll Surg 2008 0.75
82 Efficacy and toxicity of the novel chemotherapeutic agent KW-2170 in recurrent epithelial ovarian cancer. Gynecol Oncol 2006 0.75